ArticleNature2018
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 269 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
269citing papers in PubMed, 4 pooled it
17.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
269 citing papers in PubMed, 4 syntheses or guidelines pooled it, 408 citations in OpenAlex.
- Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.European urology · 2025Pooled it
- Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review.European urology · 2025Pooled it
- Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.Cell death & disease · 2022Pooled it
- PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.JCO precision oncology · 2021Pooled it
- RNASEH2B loss and PARP inhibition in advanced prostate cancer.The Journal of clinical investigation · 2024Trial
- Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.European urology · 2021Trial
- Multi-omics profiling reveals homologous recombination repair hyperactivation as a therapeutic vulnerability in neuroendocrine cervical carcinoma.Signal transduction and targeted therapy · 2026Article
- Chemogenomic maps reveal a PRDX1-dependent iron-damage axis in the DNA damage response.Nature chemical biology · 2026Article
- CRISPRing through time: How cutting-edge technology is revolutionizing life sciences and medicine.Molecular therapy. Nucleic acids · 2026Review
- The UVA-induced single-base mutational signature of CX-5461 in human cells.Nucleic acids research · 2026Article
- RTF2 and CLASPIN localize CHK1 to the replication fork to control S-phase progression.Science advances · 2026Article
- FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity.Molecular cell · 2026Article
- LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.Molecular cancer therapeutics · 2026Article
- The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.Nature communications · 2026Article
- Nucleophagy removes cytotoxic trapped PARP1.Nature cell biology · 2026Article
- Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC.Cell reports. Medicine · 2026Article
- LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling.Genome biology · 2026Article
- Synthetic lethality in cancer: mechanism exploration and therapeutic applications.Cell communication and signaling : CCS · 2026Review
- Dual-site phosphorylation of SLX4 stabilizes the SLX4-MUS81 interface to promote mitotic SMX assembly and genome protection.Nucleic acids research · 2026Article
- PARP1 regulates the genomic ribonucleotide processing activity of TOP1 to prevent the formation of toxic TOP1-DNA adducts and the associated mutations.bioRxiv : the preprint server for biology · 2026Article
209 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 11 institutions in 3 countries.
Michal ZimmermannThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Olga MurinaMRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Martin A M ReijnsMRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Angelo AgathanggelouInstitute for Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Rachel ChallisMRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Žygimantė TarnauskaitėMRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Morwenna MuirCancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK.
Adeline FluteauMRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Michael AreggerDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Andrea McEwanThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Wei YuanThe Institute of Cancer Research, London, UK.
Matthew ClarkeThe Institute of Cancer Research, London, UK.
Maryou B LambrosThe Institute of Cancer Research, London, UK.
Shankara PaneeshaHeartlands Hospital, Birmingham, UK.
Paul MossInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Megha ChandrashekharDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Stephane AngersDepartment of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy & Department of Biochemistry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Jason MoffatDonnelly Centre, University of Toronto, Toronto, Ontario, Canada.
Valerie G BruntonCancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK.
Traver HartDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Johann de BonoThe Institute of Cancer Research, London, UK.
Tatjana StankovicInstitute for Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Andrew P JacksonMRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. andrew.jackson@igmm.ed.ac.uk.
Daniel DurocherThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. durocher@lunenfeld.ca.
University of Toronto · CAInstitute of Cancer Research · GBInstitute of Genetics and Cancer · GBUniversity of Birmingham · GBUniversity of Edinburgh · GBEdinburgh Cancer Research · GBMount Sinai Hospital · CACanadian Institute for Advanced Research · CAHeartlands Hospital · GBRoyal Marsden NHS Foundation Trust · GBThe University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MMedical Research Council MC_PC_U127580972Medical Research Council MC_UU_00007/5NCI NIH HHS P30 CA016672
Abstract
The observation that BRCA1- and BRCA2-deficient cells are sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP) has spurred the development of cancer therapies that use these inhibitors to target deficiencies in homologous recombination
Indexed as
CRISPR-Cas SystemsDNA DamageGene EditingAnimalsBRCA1 ProteinCell LineDNA RepairDNA ReplicationDNA Topoisomerases, Type IFemaleGenes, BRCA1GenomeHeLa CellsHumansLeukemia, Lymphocytic, Chronic, B-CellMaleBRCA1 ProteinDNA Topoisomerases, Type IolaparibPARP1 protein, humanPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsRibonuclease Hribonuclease HIIRibonucleotidestalazoparibTOP1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.